Company Focus
Bayer
Latest Bayer News
Pharmaceutical
Germany’s Bayer saw its shares tumble almost 11% to 21.76 euros this morning, as it reported level third-quarter 2024 sales while earnings declined. 12 November 2024
Related News
Insights
Company Spotlight
A biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology.
Latest News & Features of interest to Bayer
Pharmaceutical
US clinical-stage firm ESSA Pharma has made the decision to terminate the Phase II clinical trial evaluating in a 2:1 randomization masofaniten combined with enzalutamide versus enzalutamide single agent in patients with metastatic castration-resistant prostate cancer (mCRPC) naïve to second-generation antiandrogens. 2 November 2024
Pharmaceutical
An impressive set of quarterly financial results and an improved outlook for the rest of the year were announced by Bristol Myers Squibb on Thursday. 31 October 2024
Pharmaceutical
Shares in Merck & Co were more than 2% lower as New York trading entered its latter half on Thursday. The US pharma giant earlier announced its financial results for the third quarter of 2024, along with its latest guidance for the year as a whole. 31 October 2024
Biotechnology
This morning, pharma major AbbVie and fellow USA-based EvolveImmune Therapeutics announced the signing of a collaboration and option-to-licence agreement that will leverage EvolveImmune's proprietary EVOLVE T-cell engager platform to develop novel, multispecific therapeutic antibodies for cancer. 31 October 2024
Biotechnology
Aitia, a US biotech using causal AI and Digital Twins in drug discovery and development, is expanding its collaboration with privately-held French drugmaker Servier, to tackle gliomas. 31 October 2024
Biotechnology
Regeneron Pharmaceuticals today announced financial results for the third quarter of 2024 that beat expectations, but still saw its share price fall more than 6% to $866 in early trading. 31 October 2024
Biotechnology
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine sugemalimab (trade name Eqjubi) to treat adult patients with a type of cancer called non-small cell lung cancer (NSCLC ). 31 October 2024
Biotechnology
Swiss pharma giant Roche has released detailed analysis of the positive Phase III INAVO120 results, evaluating Itovebi (inavolisib) in combination with palbociclib (Ibrance) and fulvestrant were published in the New England Journal of Medicine. 31 October 2024
Biotechnology
US biotech major Amgen late yesterday released financial results for the third quarter of 2024, showing strong sales and earnings growth. 31 October 2024
Pharmaceutical
US drugmaker Eli Lilly looked set to lose a whopping $730 million in the stock market value on Wednesday, if its lunchtime position was to be maintained. 30 October 2024
Latest In Brief for Bayer
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Latest Ones To Watch News of interest to Bayer
Although it is seeing a downturn in sales and profits, German biotech BioNTech is continuing to acquire assets with the cash pile it made through the covid pandemic, notably iis Comirnaty vaccine that was developed with Pfizer (NYSE: PFE). 13 November 2024
8 November 2024
30 October 2024
28 October 2024
26 October 2024
Ones to Watch Companies of interest to Bayer
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze